Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

(2017) N. W. Choong et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

(2010) Keith T. Flaherty et al.   CANCER BIOLOGY & THERAPY

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

(2009) Ezra EW Cohen et al.   LANCET ONCOLOGY

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

(2008) A A M van der Veldt et al.   BRITISH JOURNAL OF CANCER

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

(2008) Olwen M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Transvascular and interstitial transport in rat hepatocellular carcinomas: Dynamic contrast-enhanced MRI assessment with low- and high-molecular weight agents

(2008) Nicolas Michoux et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE